Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityNo recent work listed

Xueyi Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5429-1865; OpenAlex author ID A5000510340. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2021: 6 papers · 2022: 3 papers

Papers 9

  1. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Co-author DOI 10.1016/j.canlet.2022.215751↗
  2. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Co-author DOI 10.1038/s41419-022-05172-2↗
  3. Dynamic regulation of KIF15 phosphorylation and acetylation promotes focal adhesions disassembly in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05338-y↗
  4. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03921-3↗
  5. CircRNF13 Promotes the Malignant Progression of Pancreatic Cancer through Targeting miR-139-5p/IGF1R Axis. Co-author DOI 10.1155/2021/6945046↗
  6. Circular RNA hsa_circ_0006117 Facilitates Pancreatic Cancer Progression by Regulating the miR-96-5p/KRAS/MAPK Signaling Pathway. Co-author DOI 10.1155/2021/9213205↗
  7. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling. Co-author DOI 10.1186/s12935-021-02118-0↗
  8. CircSEC24A upregulates TGFBR2 expression to accelerate pancreatic cancer proliferation and migration via sponging to miR-606. Co-author DOI 10.1186/s12935-021-02392-y↗
  9. Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21. Co-author DOI 10.3389/fcell.2021.682131↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianxin Jiang · 9 shared papers, 2021–2022 · strength 1.43
  2. Xinyuan Liu · 7 shared papers, 2021–2022 · strength 1.12
  3. Yankun Chen · 7 shared papers, 2021–2022 · strength 1.07
  4. Jian Xu · 6 shared papers, 2021–2022 · strength 0.90
  5. Zhiwei He · 4 shared papers, 2021–2022 · strength 0.59
  6. Zhiwei He · 3 shared papers, 2021–2022 · strength 0.49
  7. Jie Wang · 2 shared papers, 2021 · strength 0.28
  8. Peng Chen · 2 shared papers, 2021 · strength 0.28
  9. Gang Quan · 1 shared paper, 2022 · strength 0.17
  10. Jie Wang · 1 shared paper, 2022 · strength 0.17
  11. Cheng-Yi Sun · 1 shared paper, 2022 · strength 0.16
  12. Tao Liu · 1 shared paper, 2021 · strength 0.15
  13. Peng Chen · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.